|
|
| Zeile 3: |
Zeile 3: |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32335367|t=ä. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response |pdf=|usr=}}
| |
| − | {{tp|p=32333222|t=ä. The genetic sequence, origin, and diagnosis of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32269085|t=ä. Pathogenesis of COVID-19 from a cell biologic perspective |pdf=|usr=}}
| |
| − | {{tp|p=32141570|t=2020. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV |pdf=|usr=}}
| |
| − | {{tp|p=32141569|t=2020. COVID-19 (Novel Coronavirus 2019) - recent trends |pdf=|usr=}}
| |
| − | {{tp|p=32329877|t=2020. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options |pdf=|usr=}}
| |
| − | {{tp|p=32317050|t=2020. Coronavirus disease (COVID-19): a scoping review |pdf=|usr=}}
| |
| − | {{tp|p=32306751|t=2020. Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| | {{tp|p=32142596|t=2020. Machine Learning, COVID?19 (2019?nCoV), and multi?OMICS |pdf=|usr=}} | | {{tp|p=32142596|t=2020. Machine Learning, COVID?19 (2019?nCoV), and multi?OMICS |pdf=|usr=}} |
| Zeile 47: |
Zeile 37: |
| | *'''[[Early symptoms]]''' | | *'''[[Early symptoms]]''' |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| − | {{tp|p=32160148|t=2020. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China |pdf=|usr=}}
| |
| − | {{tp|p=32343223|t=2020. Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient |pdf=|usr=}}
| |
| − | {{tp|p=32298228|t=2020. Panton-Valentine Leukocidin-Secreting Staphylococcus aureus Pneumonia Complicating COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32345526|t=ä. Factors associated with mortality in patients with COVID-19 A quantitative evidence synthesis of clinical and laboratory data |pdf=|usr=}}
| |
| − | {{tp|p=32290901|t=2020. Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France, March 2020 |pdf=|usr=}}
| |
| − |
| |
| | *'''[[ARDS]]''' | | *'''[[ARDS]]''' |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32334995|t=2020. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32303472|t=ä. Acute pulmonary embolism in a patient with COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32348233|t=2020. Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease |pdf=|usr=}}
| |
| − | {{tp|p=32227120|t=ä. Acute pulmonary embolism and COVID-19 pneumonia: a random association?|pdf=|usr=}}
| |
| − | {{tp|p=32338707|t=ä. Acute pulmonary embolism in conjunction with intramural right ventricular thrombus in a SARS-CoV-2-positive patient |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Hematology]]''' |
| | | | |
| − | *'''[[Hematology]]'''
| |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32363381|t=ä. Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients?|pdf=|usr=}}
| |
| − | {{tp|p=32227076|t=ä. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32196087|t=ä. SARS-CoV2: should inhibitors of the renin?angiotensin system be withdrawn in patients with COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32267502|t=ä. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection |pdf=|usr=}}
| |
| − | {{tp|p=32267494|t=ä. CAPACITY-COVID: a European registry to determine the role of cardiovascular disease in the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32285920|t=ä. Transient complete heart block in a patient with critical COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32285915|t=ä. Typical takotsubo syndrome triggered by SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32338706|t=ä. Myocarditis revealing COVID-19 infection in a young patient |pdf=|usr=}}
| |
| − | {{tp|p=32282027|t=ä. COVID-19-related myocarditis in a 21-year-old female patient |pdf=|usr=}}
| |
| − | {{tp|p=32359887|t=ä. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 83: |
Zeile 51: |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32283980|t=2020. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms |pdf=|usr=}}
| |
| − | {{tp|p=32269598|t=2020. Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?|pdf=|usr=}}
| |
| − | {{tp|p=32370982|t=ä. Ensuring mental health care during the SARS-CoV-2 epidemic in France: a narrative review |pdf=|usr=}}
| |
| − | {{tp|p=32253535|t=ä. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study |pdf=|usr=}}
| |
| − | {{tp|p=32328771|t=ä. The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32303881|t=ä. Possible link between anosmia and COVID-19: sniffing out the truth |pdf=|usr=}}
| |
| − | {{tp|p=32309267|t=2020. Anosmia and Dysgeusia in the Absence of Other Respiratory Diseases: Should COVID-19 Infection Be Considered?|pdf=|usr=}}
| |
| − | {{tp|p=32329813|t=2020. Defining the burden of olfactory dysfunction in COVID-19 patients |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| Zeile 121: |
Zeile 80: |
| | * | | * |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=32270412|t=ä. Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32342252|t=ä. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards |pdf=|usr=}}
| |
| − | {{tp|p=32329811|t=2020. The nucleic acid test of induced sputum should be used for estimation of patients cure with 2019-nCov |pdf=|usr=}}
| |
| − | {{tp|p=32156329|t=2020. Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system |pdf=|usr=}}
| |
| − | {{tp|p=32209163|t=2020. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32156330|t=2020. Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=31992387|t=2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR |pdf=|usr=}}
| |
| − | {{tp|p=32046815|t=2020. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32347204|t=2020. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32290902|t=2020. An alternative workflow for molecular detection of SARS-CoV-2 escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32290904|t=2020. Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS Foundation Trust in the United Kingdom, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32156101|t=2020. Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32297805|t=2020. Real-time RT-PCR in COVID-19 detection: issues affecting the results |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32294704|t=ä. Structured thoracic computed tomography report for COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32374802|t=ä. The halo sign as a chest computed tomography finding of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32241244|t=2020. Diagnostic value and key features of computed tomography in Coronavirus Disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32285222|t=ä. Three unsuspected CT diagnoses of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32285028|t=2020. Lung Changes on Chest CT During 2019 Novel Coronavirus (COVID-19) Pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32337662|t=ä. Classification of COVID-19 patients from chest CT images using multi-objective differential evolution?based convolutional neural networks |pdf=|usr=}}
| |
| − | {{tp|p=32107577|t=ä. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32088847|t=ä. 18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases |pdf=|usr=}}
| |
| − | {{tp|p=32198615|t=ä. The potential added value of FDG PET/CT for COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32166511|t=ä. 18F-FDG PET/CT and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32350559|t=ä. Is there a role for lung perfusion 99mTc -MAA SPECT/CT to rule out pulmonary embolism in COVID-19 patients with contraindications for iodine contrast?|pdf=|usr=}}
| |
| − | {{tp|p=32246209|t=ä. The indispensable role of chest CT in the detection of coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32342191|t=ä. FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients |pdf=|usr=}}
| |
| − | {{tp|p=32335706|t=ä. CT, 18F FDG-PET/CT and clinical findings before and during early Covid-19 onset in a patient affected by vascular tumour |pdf=|usr=}}
| |
| − | {{tp|p=32333071|t=ä. A case of COVID-19 lung infection first detected by 18F FDG PET-CT |pdf=|usr=}}
| |
| − | {{tp|p=32303786|t=ä. PET imaging of COVID-19: the target and the number |pdf=|usr=}}
| |
| − | {{tp|p=32335426|t=ä. Imaging of Coronavirus Disease 2019: A Chinese Expert Consensus Statement |pdf=|usr=}}
| |
| − | {{tp|p=32193037|t=2020. CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity |pdf=|usr=}}
| |
| − | {{tp|p=32199142|t=2020. Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings |pdf=|usr=}}
| |
| − | {{tp|p=32229322|t=2020. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?|pdf=|usr=}}
| |
| − | {{tp|p=32240913|t=2020. High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages |pdf=|usr=}}
| |
| − | {{tp|p=32334369|t=2020. Serial CT features in discharged COVID-19 patients with positive RT-PCR re-test |pdf=|usr=}}
| |
| − | {{tp|p=32289051|t=2020. COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review |pdf=|usr=}}
| |
| − | {{tp|p=32325282|t=2020. Chest CT findings of COVID-19 pneumonia by duration of symptoms |pdf=|usr=}}
| |
| − | {{tp|p=32367422|t=ä. Interpretation of CT signs of 2019 novel coronavirus (COVID-19) pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32367421|t=ä. Incidentally discovered COVID-19 pneumonia: the role of diagnostic imaging |pdf=|usr=}}
| |
| − | {{tp|p=32367418|t=ä. Imaging features and evolution on CT in 100 COVID-19 pneumonia patients in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32215691|t=ä. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32025790|t=ä. Imaging changes in patients with 2019-nCov |pdf=|usr=}}
| |
| − | {{tp|p=32211963|t=ä. Coronavirus disease 2019: initial chest CT findings |pdf=|usr=}}
| |
| − | {{tp|p=32193638|t=ä. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review |pdf=|usr=}}
| |
| − | {{tp|p=32193637|t=ä. Recommendation of low-dose CT in the detection and management of COVID-2019 |pdf=|usr=}}
| |
| − | {{tp|p=32072255|t=ä. Outbreak of novel coronavirus (COVID-19): What is the role of radiologists?|pdf=|usr=}}
| |
| − | {{tp|p=32055945|t=ä. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32270314|t=ä. What can European radiologists learn from the outbreak of COVID-19 in China? A discussion with a radiologist from Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32346790|t=2020. Coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) and common lexicon: a proposal based on the imaging data of 37 studies |pdf=|usr=}}
| |
| − | {{tp|p=32323011|t=ä. Characteristic CT findings distinguishing 2019 novel coronavirus disease (COVID-19) from influenza pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32314058|t=ä. COVID-19 patients and the radiology department ? advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI) |pdf=|usr=}}
| |
| − | {{tp|p=32300971|t=ä. A diagnostic model for coronavirus disease 2019 (COVID-19) based on radiological semantic and clinical features: a multi-center study |pdf=|usr=}}
| |
| − | {{tp|p=32296940|t=ä. The role of imaging in 2019 novel coronavirus pneumonia (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32291502|t=ä. Evolution of CT findings in patients with mild COVID-19 pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32291501|t=ä. CT features of novel coronavirus pneumonia (COVID-19) in children |pdf=|usr=}}
| |
| − | {{tp|p=32279115|t=ä. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city |pdf=|usr=}}
| |
| − | {{tp|p=32217649|t=2020. Clinical and CT features of early stage patients with COVID-19: a retrospective analysis of imported cases in Shanghai, China |pdf=|usr=}}
| |
| − | {{tp|p=32196627|t=2020. Point-of-Care Lung Ultrasound findings in novel coronavirus disease-19 pnemoniae: a case report and potential applications during COVID-19 outbreak |pdf=|usr=}}
| |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| Zeile 189: |
Zeile 88: |
| | | | |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32371555|t=2020. Utility of extracorporeal membrane oxygenation in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32357995|t=2020. Tracheal intubation in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32326959|t=2020. High-flow nasal cannula may be no safer than non-invasive positive pressure ventilation for COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=C7156900|t=2020. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series |pdf=|usr=}}
| |
| − | {{tp|p=32322959|t=ä. Tracheostomy in the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32314050|t=ä. Recommendation of a practical guideline for safe tracheostomy during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32299867|t=2020. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion |pdf=|usr=}}
| |
| − | {{tp|p=32271455|t=2020. Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Clinical guidelines and advice]]''' | | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32306118|t=ä. COVID-19 in otolaryngologist practice: a review of current knowledge |pdf=|usr=}}
| |
| − | {{tp|p=32352517|t=ä. Anticoagulation in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32265307|t=ä. Early consensus management for non-ICU ARF SARS-CoV-2 emergency in Italy: from ward to trenches |pdf=|usr=}}
| |
| − | {{tp|p=32341111|t=2020. Clinical phenotypes of SARS-CoV-2: Implications for clinicians and researchers |pdf=|usr=}}
| |
| − | {{tp|p=32269090|t=ä. Managing the supportive care needs of those affected by COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32329880|t=2020. Short Report - Medical nutrition therapy for critically ill patients with COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 211: |
Zeile 95: |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32232395|t=ä. Initial COVID-19 affecting cardiac patients in China |pdf=|usr=}}
| |
| − | {{tp|p=32324223|t=ä. Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence |pdf=|usr=}}
| |
| − | {{tp|p=32324222|t=ä. Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32236478|t=ä. Speculation is not evidence: antihypertensive therapy and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32286607|t=ä. Might renin?angiotensin system blockers play a role in the COVID-19 pandemic?|pdf=|usr=}}
| |
| − | {{tp|p=32344292|t=2020. COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors |pdf=|usr=}}
| |
| − | {{tp|p=32305831|t=ä. Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment |pdf=|usr=}}
| |
| − | {{tp|p=32328850|t=ä. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening |pdf=|usr=}}
| |
| − | {{tp|p=32322046|t=ä. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32296994|t=ä. The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments |pdf=|usr=}}
| |
| − | {{tp|p=C7141546|t=ä. Is low sodium intake a risk factor for severe and fatal COVID-19 infection?|pdf=|usr=}}
| |
| − | {{tp|p=32345527|t=ä. Smoking Habit and Hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Related Pneumonia: the unsolved paradox behind the evidence |pdf=|usr=}}
| |
| − | {{tp|p=32307204|t=ä. Intrapartum care of women with COVID-19: A practical approach |pdf=|usr=}}
| |
| − | {{tp|p=32278619|t=ä. The novel coronavirus (2019-nCoV) in pregnancy: What we need to know |pdf=|usr=}}
| |
| − | {{tp|p=32217650|t=2020. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis |pdf=|usr=}}
| |
| − | {{tp|p=32269089|t=2020. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32269087|t=ä. Novel Coronavirus Infection in Newborn Babies Under 28 Days in China |pdf=|usr=}}
| |
| − | {{tp|p=32269088|t=2020. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study |pdf=|usr=}}
| |
| − | {{tp|p=32341104|t=2020. Cardiovascular comorbidity and its impact on patients with Covid-19 |pdf=|usr=}}
| |
| − | {{tp|p=32350104|t=ä. COVID-19 and Nicotine as a Mediator of ACE-2 |pdf=|usr=}}
| |
| − | {{tp|p=32341101|t=2020. COVID-19 and Smoking Is Nicotine the Hidden Link?|pdf=|usr=}}
| |
| − | {{tp|p=32312864|t=ä. Association between ages and clinical characteristics and outcomes of coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32279905|t=ä. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Renal Failure Patients: A Potential Covert Source of Infection |pdf=|usr=}}
| |
| − | {{tp|p=32284245|t=ä. The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is ?Safe Better than Sorry??|pdf=|usr=}}
| |
| − | {{tp|p=32317180|t=ä. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32345072|t=2020. The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| Zeile 248: |
Zeile 104: |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32337324|t=2020. The Data set for Patient Information Based Algorithm to Predict Mortality Cause by COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32267826|t=2020. Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand |pdf=|usr=}}
| |
| − | {{tp|p=32208917|t=2020. The different clinical characteristics of corona virus disease cases between children and their families in China ? the character of children with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32269086|t=ä. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China |pdf=|usr=}}
| |
| − | {{tp|p=32139464|t=ä. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32271459|t=2020. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha |pdf=|usr=}}
| |
| − | {{tp|p=32347201|t=2020. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020 |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[The morbid survivor]]''' | | *'''[[The morbid survivor]]''' |
| Zeile 268: |
Zeile 116: |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32363880|t=2020. Medical treatment options for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32372695|t=2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol |pdf=|usr=}}
| |
| − | {{tp|p=32347925|t=ä. Statin therapy in COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32347923|t=ä. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety |pdf=|usr=}}
| |
| − | {{tp|p=32337546|t=ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?|pdf=|usr=}}
| |
| − | {{tp|p=32282032|t=ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients |pdf=|usr=}}
| |
| − | {{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}}
| |
| − | {{tp|p=C7129866|t=ä. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32341100|t=2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective |pdf=|usr=}}
| |
| − | {{tp|p=32265310|t=ä. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32271462|t=2020. Inositol and pulmonary function Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?|pdf=|usr=}}
| |
| − | {{tp|p=32271456|t=2020. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32271454|t=2020. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32329881|t=2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience |pdf=|usr=}}
| |
| − | {{tp|p=32329879|t=2020. (Naturlal products: )An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections |pdf=|usr=}}
| |
| − | {{tp|p=32327396|t=ä. COVID-19 and Bacillus Calmette-Guerin: What is the Link?|pdf=|usr=}}
| |
| − | {{tp|p=32279655|t=2020. Can Hepatitis A Vaccine Provide Protection Against COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32250170|t=2020. Will plant-made biopharmaceuticals play a role in the fight against COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32329380|t=2020. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32117569|t=2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32212513|t=2020. The Trial of Chloroquine in the Treatment of Corona Virus Disease 2019 COVID-19 and Its Research Progress in Forensic Toxicology |pdf=|usr=}}
| |
| − | {{tp|p=32269766|t=2020. In silico identification of vaccine targets for 2019-nCoV |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| | *'''[[Other routes of infection]]''' | | *'''[[Other routes of infection]]''' |
| − | {{tp|p=32241022|t=ä. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32297915|t=ä. Comment of the potential risks of sexual and vertical transmission of Covid-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32243255|t=2020. Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations |pdf=|usr=}}
| |
| − | {{tp|p=32342724|t=2020. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient |pdf=|usr=}}
| |
| − | {{tp|p=32336661|t=ä. Is there evidence of intra-uterine vertical transmission potential of COVID-19 infection in samples tested by quantitative RT-PCR?|pdf=|usr=}}
| |
| − | {{tp|p=32355863|t=2020. SARS-CoV-2 in the ocular surface of COVID-19 patients |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32324531|t=2020. The Practice of Wearing Surgical Masks during the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32284092|t=2020. Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub Formulations and Alcohols |pdf=|usr=}}
| |
| − | {{tp|p=32282025|t=ä. Donning and doffing of personal protective equipment (PPE) for angiography during the COVID-19 crisis |pdf=|usr=}}
| |
| − | {{tp|p=32248146|t=2020. Protecting healthcare workers from SARS-CoV-2 infection: practical indications |pdf=|usr=}}
| |
| − | {{tp|p=32350103|t=ä. Universal use of face masks for success against COVID-19: evidence and implications for prevention policies |pdf=|usr=}}
| |
| − | {{tp|p=32271461|t=2020. COVID-19: emerging protective measures |pdf=|usr=}}
| |
| − | {{tp|p=32329812|t=2020. Just one more hygiene practice in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32327740|t=ä. Controversies regarding mask usage in ophthalmic units in the United Kingdom during the COVID-19 pandemic |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | * | | * |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32228737|t=ä. COVID-19 disease emergency operational instructions for Mental Health Departments issued by the Italian Society of Epidemiological Psychiatry |pdf=|usr=}} | + | {{tp|p=32367256|t=ä. Nuclear medicine services after COVID-19: gearing up back to normality |pdf=|usr=}} |
| − | {{tp|p=32303485|t=ä. French consensus on management of head and neck cancer surgery during COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32338298|t=ä. The After Diagnosis Head and Neck cancer-specific Patient Concerns Inventory (HaNC-AD) as a pre-treatment preparation aid during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32232396|t=ä. Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32361812|t=ä. Mental health treatment online during the COVID-19 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32338764|t=ä. A treatment strategy for acute myocardial infarction and personal protection for medical staff during the COVID-19 epidemic: the Chinese experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32286606|t=ä. Priorities for Cath labs in the COVID-19 tsunami: Roberto Ferrari and co-authors present a procedure to follow subsequent to the outbreak in Italy |pdf=|usr=}}
| + | |
| − | {{tp|p=32320040|t=ä. Health system, public health, and economic implications of managing COVID-19 from a cardiovascular perspective |pdf=|usr=}}
| + | |
| − | {{tp|p=32242891|t=ä. COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel |pdf=|usr=}}
| + | |
| − | {{tp|p=32285027|t=2020. Breast Cancer Diagnosis, Treatment and Follow-Up During COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32285026|t=2020. Sars-CoV-2 (COVID-19) Outbreak and Breast Cancer Surgery in Turkey |pdf=|usr=}}
| + | |
| − | {{tp|p=32305011|t=2020. Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)?related disease pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32294611|t=2020. A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19?positive patients with cancer |pdf=|usr=}}
| + | |
| − | {{tp|p=32361628|t=ä. Lessons from the COVID-19 pandemic ? will virtual patient management reshape uro-oncology in Germany?|pdf=|usr=}}
| + | |
| − | {{tp|p=32302754|t=2020. Managing patients with cancer in the COVID-19 era |pdf=|usr=}}
| + | |
| − | {{tp|p=32301984|t=ä. The COVID-19 outbreak and its impact on hospitals in Italy: the model of cardiac surgery |pdf=|usr=}}
| + | |
| − | {{tp|p=32301976|t=ä. Management of elective aortic valve replacement over the long term in the era of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32243318|t=2020. COVID-19: emergency medicine perspectives from Hong Kong |pdf=|usr=}}
| + | |
| − | {{tp|p=32243317|t=2020. European Society For Emergency Medicine position paper on emergency medical systems? response to COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32229768|t=2020. COVID-19: response plan for International Medical Assistance companies |pdf=|usr=}}
| + | |
| − | {{tp|p=32224710|t=2020. How emergency departments prepare for virus disease outbreaks like COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32205709|t=2020. The challenge of emergency medicine facing the COVID-19 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32345851|t=2020. The emergency department in the COVID-19 era Who are we missing?|pdf=|usr=}}
| + | |
| − | {{tp|p=32362361|t=ä. Non-SARS CoV2 positive critical patients: sons of a lesser God?|pdf=|usr=}}
| + | |
| − | {{tp|p=32215677|t=ä. Suggestions for safety and protection control in Department of Nuclear Medicine during the outbreak of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32232520|t=ä. Facing a disruptive threat: how can a nuclear medicine service be prepared for the coronavirus outbreak 2020?|pdf=|usr=}}
| + | |
| − | {{tp|p=32318782|t=ä. Key elements of preparedness for pandemic coronavirus disease 2019 (COVID-19) in nuclear medicine units |pdf=|usr=}}
| + | |
| − | {{tp|p=32296886|t=ä. COVID-19 pandemic: guidance for nuclear medicine departments |pdf=|usr=}}
| + | |
| − | {{tp|p=32296884|t=ä. Nuclear medicine in responding to global pandemic COVID-19?American College of Nuclear Medicine member experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32303841|t=ä. Lead the way or leave the way: leading a Department of Orthopedics through the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32225137|t=2020. Facing in real time the challenges of the Covid-19 epidemic for rehabilitation |pdf=|usr=}}
| + | |
| − | {{tp|p=32175719|t=2020. Impact of COVID-19 outbreak on rehabilitation services and Physical and Rehabilitation Medicine (PRM) physicians activities in Italy An official document of the Italian PRM Society (SIMFER) |pdf=|usr=}}
| + | |
| − | {{tp|p=32327266|t=ä. Pre-labor anorectal swab for SARS-CoV-2 in COVID-19 pregnant patients: is it time to think about it?|pdf=|usr=}}
| + | |
| − | {{tp|p=32264667|t=2020. First impact on services and their preparation "Instant paper from the field" on rehabilitation answers to the Covid-19 emergency |pdf=|usr=}}
| + | |
| − | {{tp|p=32329593|t=2020. Telemedicine from research to practice during the pandemic "Instant paper from the field" on rehabilitation answers to the Covid-19 emergency |pdf=|usr=}}
| + | |
| − | {{tp|p=32329592|t=2020. Organization of acute patients transfer to rehabilitation services during COVID-19 crisis |pdf=|usr=}}
| + | |
| − | {{tp|p=32329590|t=2020. Impact of coronavirus disease 2019 (covid-19) outbreak on rehabilitation services and physical medicine and rehabilitation (PM&R) physicians activities: perspectives from the Spanish experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32329591|t=2020. Covid-19 and child disabilities: whom to protect and how |pdf=|usr=}}
| + | |
| − | {{tp|p=32293816|t=2020. The impact of covid-19 on rehabilitation services and activities Letter to the editor in response to official document of SIMFER |pdf=|usr=}}
| + | |
| − | {{tp|p=32313348|t=ä. Nosocomial infections in psychiatric hospitals during the new coronavirus pneumonia outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32344294|t=2020. Radiology department strategies to protect radiologic technologists against COVID19: Experience from Wuhan |pdf=|usr=}}
| + | |
| − | {{tp|p=32336627|t=ä. The need of COVID19 free hospitals to maintain cancer care |pdf=|usr=}}
| + | |
| − | {{tp|p=32359919|t=ä. COVID-19: The European institute of oncology as a hub centre for breast cancer surgery during the pandemic in Milan (Lombardy region, northern Italy) - A screenshot of the first month |pdf=|usr=}}
| + | |
| − | {{tp|p=32371040|t=ä. Rationalizing breast cancer surgery during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32362468|t=ä. Cancer surgery in a time of COVID-19: Many questions, few certainties |pdf=|usr=}}
| + | |
| − | {{tp|p=32371041|t=ä. Cancer care under the outbreak of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32336625|t=ä. Coronavirus outbreak: Reorganising the breast unit during a pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32359918|t=2020. Management of Gynaecological oncology diseases during COVID-19 global pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32331984|t=ä. Surgical management of bone and soft tissue sarcomas and skeletal metastases during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32312591|t=ä. Cancer care under the outbreak of COVID-19: A perspective from Italian tertiary referral center for surgical oncology |pdf=|usr=}}
| + | |
| − | {{tp|p=32347329|t=ä. Surgical management of suspected or confirmed SARS-CoV-2 (COVID-19)-positive patients: a model stemming from the experience at Level III Hospital in Emilia-Romagna, Italy |pdf=|usr=}}
| + | |
| − | {{tp|p=32313969|t=ä. Personal reflections of an emergency general surgeon on the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32303798|t=ä. European Society of Trauma and Emergency Surgery (ESTES) recommendations for trauma and emergency surgery preparation during times of COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32303451|t=ä. The Need of Research Initiatives Amidst and After the Covid-19 Pandemic: A Message from the Editors of the European Journal of Vascular and Endovascular Surgery |pdf=|usr=}}
| + | |
| − | {{tp|p=32307223|t=ä. Challenges of methadone maintenance treatment during the COVID-19 epidemic in China: policy and service recommendations |pdf=|usr=}}
| + | |
| − | {{tp|p=32234102|t=ä. The consequences of the COVID-19 pandemic on mental health and implications for clinical practice |pdf=|usr=}}
| + | |
| − | {{tp|p=32328761|t=ä. Adapting to a new normal? 5 key operational principles for a radiology service facing the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32356161|t=ä. Important lessons for infection control in radiology departments during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32318843|t=ä. The Radiology Department during the COVID-19 pandemic: a challenging, radical change |pdf=|usr=}}
| + | |
| − | {{tp|p=32300968|t=ä. Prevention and control measures in radiology department for COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32198275|t=2020. More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China |pdf=|usr=}}
| + | |
| − | {{tp|p=32312865|t=ä. Covid19: minimising risk to healthcare workers during aerosol producing respiratory therapy using an innovative constant flow canopy |pdf=|usr=}}
| + | |
| − | {{tp|p=32273180|t=ä. What Does COVID-19 Mean for the Pathology-Urology Interaction?|pdf=|usr=}}
| + | |
| − | {{tp|p=32279903|t=ä. Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32329810|t=2020. In the face of the SARS-CoV-2 outbreak, do people suffering from oncological disease need specific attention?|pdf=|usr=}}
| + | |
| − | {{tp|p=32362496|t=ä. Urolithiasis Practice Patterns Following the COVID-19 Pandemic: Overview from the EULIS Collaborative Research Working Group |pdf=|usr=}}
| + | |
| − | {{tp|p=32362498|t=ä. Telemedicine Online Visits in Urology During the COVID-19 Pandemic?Potential, Risk Factors, and Patients? Perspective |pdf=|usr=}}
| + | |
| − | {{tp|p=32360050|t=2020. VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32349934|t=ä. The Impact of COVID-19 Outbreak on Uro-oncological Practice Across Europe: Which Burden of Activity Are We Facing Ahead?|pdf=|usr=}}
| + | |
| − | {{tp|p=32349928|t=ä. Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guerin for High-risk Non?muscle-invasive Bladder Cancer During the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32349936|t=ä. Balancing the Effects of COVID-19 Against Potential Progression and Mortality in High-risk Prostate Cancer |pdf=|usr=}}
| + | |
| − | {{tp|p=32349933|t=ä. Widespread Postponement of Functional Urology Cases During the COVID-19 Pandemic: Rationale, Potential Pitfalls, and Future Consequences |pdf=|usr=}}
| + | |
| − | {{tp|p=32345522|t=ä. COVID-19: Importance of the Awareness of the Clinical Syndrome by Urologists |pdf=|usr=}}
| + | |
| − | {{tp|p=32349932|t=ä. Surgical Volume, Safety, Drug Administration, and Clinical Trials During COVID-19: Single-center Experience in Shanghai, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32345523|t=ä. The Shifting Landscape of Genitourinary Oncology During the COVID-19 Pandemic and how Italian Oncologists Reacted: Results from a National Survey |pdf=|usr=}}
| + | |
| − | {{tp|p=32312544|t=ä. Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32334884|t=ä. Traditional and Virtual Congress Meetings During the COVID-19 Pandemic and the Post-COVID-19 Era: Is it Time to Change the Paradigm?|pdf=|usr=}}
| + | |
| − | {{tp|p=32331707|t=ä. Impact of the COVID-19 Pandemic on Paediatric Urology Practice in Europe: A Reflection from the European Association of Urology Young Academic Urologists |pdf=|usr=}}
| + | |
| − | {{tp|p=32303384|t=ä. Endourological Stone Management in the Era of the COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32336644|t=ä. Risk of SARS-CoV-2 Diffusion when Performing Minimally Invasive Surgery During the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32307215|t=ä. Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres |pdf=|usr=}}
| + | |
| − | {{tp|p=32372754|t=2020. Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 |pdf=|usr=}}
| + | |
| − | {{tp|p=32265003|t=2020. Indications for healthcare surge capacity in European countries facing an exponential increase in coronavirus disease (COVID-19) cases, March 2020 |pdf=|usr=}}
| + | |
| − | {{tp|p=32366999|t=ä. Current safety preferences for intravitreal injection during COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32265510|t=ä. Survey of ophthalmology practitioners in A&E on current COVID-19 guidance at three Major UK Eye Hospitals |pdf=|usr=}}
| + | |
| − | {{tp|p=32346106|t=ä. When ophthalmologists step up to the COVID-19 frontlines |pdf=|usr=}}
| + | |
| − | {{tp|p=32350447|t=ä. Implications of COVID-19 for uveitis patients: perspectives from Hong Kong |pdf=|usr=}}
| + | |
| − | {{tp|p=32317790|t=ä. Maintenance of ophthalmic specialist out-patient service during the COVID-19 outbreak: The University of Hong Kong experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32313170|t=ä. Reorganize and survive?a recommendation for healthcare services affected by COVID-19?the ophthalmology experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32291402|t=ä. Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy |pdf=|usr=}}
| + | |
| − | {{tp|p=32289038|t=2020. A comprehensive Chinese experience against SARS-CoV-2 in ophthalmology |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| Zeile 424: |
Zeile 140: |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32339092|t=2020. Decreased Influenza Incidence under COVID-19 Control Measures, Singapore |pdf=|usr=}}
| |
| − | {{tp|p=32339091|t=2020. Collateral Benefit of COVID-19 Control Measures on Influenza Activity, Taiwan |pdf=|usr=}}
| |
| − | {{tp|p=32297932|t=ä. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage |pdf=|usr=}}
| |
| − | {{tp|p=32348457|t=ä. Where have the STEMIs gone during COVID-19 lockdown?|pdf=|usr=}}
| |
| − | {{tp|p=32318915|t=ä. Vaccine confidence in the time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32289789|t=ä. The Baffling Case of Ischemic Stroke Disappearance from the Casualty Department in the COVID-19 Era |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 438: |
Zeile 148: |
| | * | | * |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=C7151430|t=ä. Airborne transmission of SARS-CoV-2: the world should face the reality |pdf=|usr=}}
| |
| − | {{tp|p=32363409|t=2020. SARS-CoV-2 spread in Northern Italy: what about the pollution role?|pdf=|usr=}}
| |
| − | {{tp|p=32283458|t=2020. COVID-19 as a factor influencing air pollution?|pdf=|usr=}}
| |
| − | {{tp|p=32268945|t=ä. Can atmospheric pollution be considered a co-factor in extremely high level of SARS-CoV-2 lethality in Northern Italy?? |pdf=|usr=}}
| |
| − | {{tp|p=32361082|t=2020. Food safety issues related to wildlife have not been taken seriously from SARS to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32353790|t=2020. Biomass use and COVID-19: A novel concern |pdf=|usr=}}
| |
| − | {{tp|p=32330766|t=ä. Is temperature reducing the transmission of COVID-19 ?|pdf=|usr=}}
| |
| − | {{tp|p=32202420|t=ä. An Imperative Need for Research on the Role of Environmental Factors in Transmission of Novel Coronavirus (COVID-19) |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32367256|t=ä. Nuclear medicine services after COVID-19: gearing up back to normality |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 463: |
Zeile 163: |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32323978|t=ä. Letter to the Editor: Wastewater-Based Epidemiology Can Overcome Representativeness and Stigma Issues Related to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32202421|t=ä. Can a Paper-Based Device Trace COVID-19 Sources with Wastewater-Based Epidemiology?|pdf=|usr=}}
| |
| − | {{tp|p=32311865|t=2020. Prevention of exposure and dispersion of COVID-19 using air purifiers: challenges and concerns |pdf=|usr=}}
| |
| − | {{tp|p=32375455|t=2020. Prediction of COVID-19 transmission dynamics using a mathematical model considering behavior changes in Korea |pdf=|usr=}}
| |
| − | {{tp|p=32345002|t=2020. Joint Statement of the Korean Society for Preventive Medicine and the Korean Society of Epidemiology on the response to the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32345000|t=2020. Urgent appeal to minimize community health impacts of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32345001|t=2020. Recommendations to the government following the declaration of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32344999|t=2020. Preparedness and response to community spread of COVID-19 governmental and national recommendations for COVID-19 by the Pan-Academic Action Committee |pdf=|usr=}}
| |
| − | {{tp|p=32344998|t=2020. Joint Statement of the Korean Society for Preventive Medicine and the Korean Society of Epidemiology on the response to the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32344997|t=2020. Professional academic organizations on infectious disease Joint Statement on COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32192278|t=2020. WHO International Health Regulations Emergency Committee for the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32164053|t=2020. Estimating the reproductive number and the outbreak size of COVID-19 in Korea |pdf=|usr=}}
| |
| − | {{tp|p=32035431|t=2020. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea |pdf=|usr=}}
| |
| − | {{tp|p=32023775|t=2020. An interim review of the epidemiological characteristics of 2019 novel coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32202489|t=ä. Risk of COVID-19 importation to the Pacific islands through global air travel |pdf=|usr=}}
| |
| − | {{tp|p=32100667|t=ä. Passengers destinations from China: low risk of Novel Coronavirus (2019-nCoV) transmission into Africa and South America |pdf=|usr=}}
| |
| − | {{tp|p=32242790|t=ä. The challenges and considerations of community-based preparedness at the onset of COVID-19 outbreak in Iran, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32373189|t=2020. Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32352515|t=ä. The battle against COVID-19: mortality in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32255475|t=ä. Denominator matters in estimating COVID-19 mortality rates |pdf=|usr=}}
| |
| − | {{tp|p=32255476|t=ä. COVID-19 experience in Bergamo, Italy |pdf=|usr=}}
| |
| − | {{tp|p=32255477|t=ä. Strategies to control COVID-19 and future pandemics in Africa and around the globe |pdf=|usr=}}
| |
| − | {{tp|p=32352314|t=2020. The COVID-19 epidemic, its mortality, and the role of non-pharmaceutical interventions |pdf=|usr=}}
| |
| − | {{tp|p=32347745|t=ä. Ethical aspects of the COVID-19 crisis: How to deal with an overwhelming shortage of acute beds |pdf=|usr=}}
| |
| − | {{tp|p=32003000|t=2020. The novel Chinese coronavirus (2019?nCoV) infections: Challenges for fighting the storm |pdf=|usr=}}
| |
| − | {{tp|p=32270413|t=ä. A family cluster of severe acute respiratory syndrome coronavirus 2 infections |pdf=|usr=}}
| |
| − | {{tp|p=32291542|t=ä. The epidemiology and clinical information about COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32306149|t=ä. Covid-19 epidemic in Italy: evolution, projections and impact of government measures |pdf=|usr=}}
| |
| − | {{tp|p=32318914|t=ä. The paramount importance of serological surveys of SARS-CoV-2 infection and immunity |pdf=|usr=}}
| |
| − | {{tp|p=32328991|t=ä. COVID-19 and the need of targeted inverse quarantine |pdf=|usr=}}
| |
| − | {{tp|p=32309108|t=2020. Mathematical prediction of the time evolution of the COVID-19 pandemic in Italy by a Gauss error function and Monte Carlo simulations |pdf=|usr=}}
| |
| − | {{tp|p=32366488|t=2020. Nosocomial Outbreak of 2019 Novel Coronavirus Pneumonia in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32269084|t=2020. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities |pdf=|usr=}}
| |
| − | {{tp|p=32299861|t=2020. The influence of preventive strategies on the COVID-2019 epidemic in Shenzhen, China |pdf=|usr=}}
| |
| − | {{tp|p=32139462|t=ä. Epidemiological characteristics of 2019-ncoV infections in Shaanxi, China by February 8, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32271458|t=2020. A classifier prediction model to predict the status of Coronavirus COVID-19 patients in South Korea |pdf=|usr=}}
| |
| − | {{tp|p=32329878|t=2020. Deep thought of COVID-19 based on Diamond Princess s quarantine and home quarantine |pdf=|usr=}}
| |
| − | {{tp|p=32329814|t=2020. Quarantine hospitals are essential for COVID-19 contention |pdf=|usr=}}
| |
| − | {{tp|p=32234121|t=2020. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32234119|t=2020. Updated rapid risk assessment from ECDC on coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK |pdf=|usr=}}
| |
| − | {{tp|p=32234117|t=2020. Potential short-term outcome of an uncontrolled COVID-19 epidemic in Lombardy, Italy, February to March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32234116|t=2020. Coronavirus disease (COVID-19) Community Testing Team in Scotland: A 14-day review, 6 to 20 February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32234115|t=2020. Rapid assessment of regional SARS-CoV-2 community transmission through a convenience sample of healthcare workers, the Netherlands, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32209164|t=2020. Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32186277|t=2020. Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom, 1 January to 15 March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32183937|t=2020. Updated rapid risk assessment from ECDC on the novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK |pdf=|usr=}}
| |
| − | {{tp|p=32183935|t=2020. Retrospective analysis of the possibility of predicting the COVID-19 outbreak from Internet searches and social media data, China, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32183930|t=2020. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32156332|t=2020. Potential scenarios for the progression of a COVID-19 epidemic in the European Union and the European Economic Area, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32156331|t=2020. Updated rapid risk assessment from ECDC on the outbreak of COVID-19: increased transmission globally |pdf=|usr=}}
| |
| − | {{tp|p=32156327|t=2020. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32019669|t=2020. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32019667|t=2020. Novel coronavirus (2019-nCoV) early-stage importation risk to Europe, January 2020 |pdf=|usr=}}
| |
| − | {{tp|p=31992388|t=2020. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32127126|t=2020. Latest assessment on COVID-19 from the European Centre for Disease Prevention and Control (ECDC) |pdf=|usr=}}
| |
| − | {{tp|p=32127124|t=2020. Early transmission patterns of coronavirus disease 2019 (COVID-19) in travellers from Wuhan to Thailand, January 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32070466|t=2020. Latest updates on COVID-19 from the European Centre for Disease Prevention and Control |pdf=|usr=}}
| |
| − | {{tp|p=32070465|t=2020. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32046819|t=2020. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20?28 January 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32046816|t=2020. Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV) |pdf=|usr=}}
| |
| − | {{tp|p=32046814|t=2020. Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32019636|t=2020. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern |pdf=|usr=}}
| |
| − | {{tp|p=32372756|t=2020. Letter to the editor: Evidence on school closure and children?s social contact: useful for coronavirus disease (COVID-19)?|pdf=|usr=}}
| |
| − | {{tp|p=32372755|t=2020. Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32372753|t=2020. Temporal rise in the proportion of younger adults and older adolescents among coronavirus disease (COVID-19) cases following the introduction of physical distancing measures, Germany, March to April 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32347198|t=2020. Epidemiological characteristics of the first 53 laboratory-confirmed cases of COVID-19 epidemic in Hong Kong, 13 February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32347200|t=2020. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32317053|t=2020. SARS-CoV2 infection and primary school closure |pdf=|usr=}}
| |
| − | {{tp|p=32290905|t=2020. A hundred days into the coronavirus disease (COVID-19) pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32317051|t=2020. Potential lethal outbreak of coronavirus disease (COVID-19) among the elderly in retirement homes and long-term facilities, France, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32265005|t=2020. Only strict quarantine measures can curb the coronavirus disease (COVID-19) outbreak in Italy, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32265008|t=2020. Understanding coronavirus disease (COVID-19) risk perceptions among the public to enhance risk communication efforts: a practical approach for outbreaks, Finland, February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32321324|t=2020. A deadly spillover: SARS-CoV-2 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32237901|t=2020. Immune-epidemiological parameters of the novel coronavirus ? a perspective |pdf=|usr=}}
| |
| − | {{tp|p=32348380|t=2020. Trends and Prediction in Daily New Cases and Deaths of COVID-19 in the United States: An Internet Search-Interest Based Model |pdf=|usr=}}
| |
| − | {{tp|p=32322535|t=ä. Socially distanced school-based nutrition program feeding under COVID 19 in the rural Niger Delta |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=32246996|t=ä. The SARS-CoV-2 epidemic: how the Italian public is being informed |pdf=|usr=}}
| |
| − | {{tp|p=32292239|t=2020. Unpacking the black box: How to promote citizen engagement through government social media during the COVID-19 crisis |pdf=|usr=}}
| |
| − | {{tp|p=32252845|t=ä. Adaptation of the National Plan for the Prevention and Fight Against Pandemic Influenza to the 2020 COVID-19 Epidemic in France |pdf=|usr=}}
| |
| − | {{tp|p=32224712|t=2020. COVID-19, a UK perspective |pdf=|usr=}}
| |
| − | {{tp|p=32271457|t=2020. Mask crisis during the COVID-19 outbreak |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 565: |
Zeile 181: |
| | *[[coviki state of development]] | | *[[coviki state of development]] |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32253375|t=ä. Nutritional management in hospital setting during SARS-CoV-2 pandemic: a real-life experience |pdf=|usr=}}
| |
| − | {{tp|p=32313188|t=ä. Nutrition amid the COVID-19 pandemic: a multi-level framework for action |pdf=|usr=}}
| |
| − | {{tp|p=32286533|t=ä. Nutritional recommendations for CoVID-19 quarantine |pdf=|usr=}}
| |
| − | {{tp|p=32293675|t=ä. Key words to be adopted for COVID-19 research: A return to simple, large, randomized trials |pdf=|usr=}}
| |
| − | {{tp|p=32362362|t=ä. COVID-19: Timing is Important |pdf=|usr=}}
| |
| − | {{tp|p=32361966|t=ä. A safe flight for children through COVID-19 disaster: keeping our mind open!|pdf=|usr=}}
| |
| − | {{tp|p=32362487|t=ä. New Data and the Covid-19 Pandemic Mandate a Rethink of Antiplatelet Strategies in Patients With TIA or Minor Stroke Associated With Atherosclerotic Carotid Stenosis |pdf=|usr=}}
| |
| − | {{tp|p=32271460|t=2020. Coronavirus disease 2019: a bibliometric analysis and review |pdf=|usr=}}
| |
| − | {{tp|p=32196628|t=2020. Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2 Would a rose by another name smell as sweet?|pdf=|usr=}}
| |
| − | {{tp|p=32141586|t=2020. Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches?|pdf=|usr=}}
| |
| − | {{tp|p=31992390|t=2020. Note from the editors: novel coronavirus (2019-nCoV) |pdf=|usr=}}
| |
| − | {{tp|p=32127122|t=2020. Letter to the editor: Plenty of coronaviruses but no SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32127123|t=2020. Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32279654|t=2020. COVID-19 UPDATE |pdf=|usr=}}
| |
| − | {{tp|p=32241685|t=ä. Climate Change, Covid-19, Preparedness, and Consciousness |pdf=|usr=}}
| |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| | *[http://www.okaybio.com covid19 antibodies, proteins & reagents] | | *[http://www.okaybio.com covid19 antibodies, proteins & reagents] |
| | *[http://www.reactionbiology.com 700 kinsse assays] | | *[http://www.reactionbiology.com 700 kinsse assays] |
